Skip to Main Content
Directory of Faculty Research Interests
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Jill Lacy, MD

Professor of Medicine (Medical Oncology)

Contact Information

Jill Lacy, MD
Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Jill Lacy is a Professor of Medicine in the Section of Medical Oncology at the Yale School of Medicine. She has a large clinical practice in the Gastrointestinal Malignancies Unit at Smilow Cancer Center, and she has been actively engaged in clinical investigation, focusing on therapeutic clinical trials. She has developed and conducted several investigator-initiated trials in gastrointestinal malignancies, and, in addition, has served as the site Principle Investigator on dozens of cooperative group and industry sponsored trials, leading to co-authorship in high impact journals. Her specific research interests include discovery of novel therapeutics for gastroesophageal and pancreatic cancers. In her role as an investigator in the Smilow Cancer Center Disease Aligned Research Team for GI Malignancies, she has been instrumental in developing the clinical trials portfolio and fostering translational research for GI Cancers at Yale.

Extensive Research Description

Dr. Jill Lacy is a Professor of Medicine in the Section of Medical Oncology at the Yale School of Medicine. She has a large clinical practice in the Gastrointestinal Malignancies Unit at Smilow Cancer Center. After transitioning from lab-based basic research in the field of EBV-associated malignancies, she has been actively engaged in clinical investigation, focusing on therapeutic clinical trials. She has developed and conducted several investigator-initiated trials, and, in addition, has served as the site Principle Investigator on dozens of cooperative group and industry sponsored trials, leading to co-authorship in high impact journals. Her specific research interests include discovery of novel therapeutics for gastroesophageal and pancreatic cancers. In her role as an investigator in the Smilow Cancer Center Disease Aligned Research Team for GI Malignancies, she has been instrumental in developing the clinical trials portfolio and fostering translational research for GI Cancers at Yale. In addition to her involvement in patient care and research, Dr. Lacy served at the Program Director of the Hematology-Medical Oncology Fellowship Program at Yale for over 20 years, playing an active role in mentoring Fellows in their research projects and development. Aligned with this commitment to education, she has been actively involved in ASCO in issues related to trainee education, including service as Editor of the ASCO Self-Evaluation Program.

Coauthors

Public Health Interests

Cancer; Clinical Trials

Selected Publications

Clinical Trials

ConditionsStudy Title
Other Endocrine System; PancreasRandomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
PancreasA Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Liver; Lung; Melanoma, skin; Other Female GenitalPhase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma
Phase IA Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors
PancreasPhase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
LiverAtezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
ColonColon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
ColonA Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)
Edit Profile